Neovii Pharmaceuticals AG (Neovii) and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd (Fosun Pharma Industry), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, a global pharmaceutical and healthcare industry group deep-rooted in China, have entered into an exclusive agreement, under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii's Grafalon (rabbit anti-human T-lymphocyte globulin, ATLG) in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region. Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon to Fosun Pharma. In addition, Fosun Pharma has the right to authorize its subsidiaries to specifically commercialize Grafalon. Grafalon (Rabbit anti-human T-lymphocyte globulin, ATLG, formerly also known as "ATG-Fresenius S" and "ATG-F") was developed by Neovii and is used to improve patients' outcomes in transplantation medicine in more than 50 countries and, in selected countries, also to treat aplastic anaemia. With more than 250,000 treated patients, 30 years of clinical experience and leadership position in many countries, Grafalon has transformed the way transplant teams manage the care of their patients and is uniquely addressing significant unmet needs. The parties' aim is to firstly strengthen Grafalon's position in the field of transplantation medicine in China, in which it is already approved for marketing and included in China's National Reimbursement Drug List. Further, the Agreement entails clinical development to expand Grafalon's regulatory approval in China to the prevention of Graft versus Host Disease following allogenic stem cell transplantation ("SCT"), so as to align its usages in China with those in Europe and other countries worldwide. Additional objective is to evolve Grafalon's usages from transplantation medicine to auto-immune and onco-haematology conditions, where Grafalon has the potential to positively-transform the lives of patients suffering from severe diseases with high unmet need. The Agreement also sets the foundation to expanding the cooperation to additional products of Neovii, starting from NB-15, a novel, clinical-stage therapy that is under development for the treatment of Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), an ultra-rare, devastating and uniformly fatal disorder. Dr. Christian Loss, CEO of Neovii said:
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!